Mitochondrial Priming Is Heterogenous in t(4;14) Multiple Myeloma and Can be Induced By Inhibition of NSD2
Matulis S, Chavez R, Owens R, Wiita A, Shanmugam M, De Matos Simoes R, Mitsiades C, Joseph N, Hofmeister C, Kaufman J, Dhodapkar M, Lonial S, Nooka A, Gupta V, Licht J, Barwick B, Boise L. Mitochondrial Priming Is Heterogenous in t(4;14) Multiple Myeloma and Can be Induced By Inhibition of NSD2. Blood 2024, 144: 4663-4663. DOI: 10.1182/blood-2024-210441.Peer-Reviewed Original ResearchDynamic BH3 profilingSensitivity to venetoclaxBH3 profilingCyto c releaseT(4;14) MMMultiple myelomaBCL2 family membersVenetoclax sensitivityBroad-spectrum peptideMitochondrial primingC releaseTKO cellsPatient samplesTreatment of multiple myelomaResistance to venetoclaxResponse to venetoclaxPredicting clinical responseT(4;14) multiple myelomaPlasma cell biologyMM cell linesAnnexin V/propidium iodide stainingHigh-risk formsDays of treatmentPrecision medicine approachBCL2 inhibition